PDE4D and nonpapillary renal cell carcinoma: They showed that targeting PDE4D with roflumilast or its knockout using CRISPR/Cas9 reduces the progression of ccRCC cells and enhances the apoptotic effect of sorafenib via attenuating MAPK/ERK signaling in a CRAF-dependent manner (114).